Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5267-5276

  Kohno, Shigeru ^a   Yen, Muh Yong ^h   Cheong, Hee Jin ⁱ   Hirotsu, Nobuo ^b   Ishida, Tadashi ^d   Kadota, Jun Ichi ^e   Mizuguchi, Masashi ^f   Kida, Hiroshi ^g   Shimada, Jingoro ^c  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hirotsu Clinic   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e OITA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g HOKKAIDO UNIVERSITY   (Japan)

^h NATIONAL YANG MING UNIVERSITY   (Taiwan)

ⁱ Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; PLACEBO;

ADULT; AGED; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLUENZA; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEASONAL INFLUENZA; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CYCLOPENTANES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GUANIDINES; HUMANS; INFLUENZA, HUMAN; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSELTAMIVIR; YOUNG ADULT;

EID: 80054709041     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00360-11     Document Type: Article

References (26)

1. Babu, Y. S., et al. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43:3482-3486.
2. Bantia, S., et al. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. (Pubitemid 32230997)
3. Bloom, J. D., L. I. Gong, and D. Baltimore. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272-1275.
4. Dharan, N. J., et al. 2010. Antiviral treatment of patients with oseltamivirresistant seasonal influenza A (H1N1) infection during the 2007-2008 influenza season in the United States. Clin. Infect. Dis. 50:621-622.
5. Dharan, N. J., et al. 2009. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301:1034-1041.
6. Hayden, F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48:S3-S13.
7. Hurt, A. C., et al. 2009. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 83:90-93.
8. Kamigaki, T., and H. Oshitani. 2009. Epidemiological characteristics and low case fatality rate of pandemic (H1N1) 2009 in Japan. PLoS Curr. 1:RRN1139.
9. Kashiwagi, S., S. Kudoh, A. Watanabe, and I. Yoshimura. 2000. Clinical efficacy and safety of selective oral neuraminidase inhibitor oseltamivir in treating acute influenza: placebo controlled double-blind multicenter phase III trial. Kansenshogaku Zasshi 74:1044-1061. (In Japanese.)
10. Kawai, N., et al. 2009. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin. Infect. Dis. 49:1828-1835.
11. Kawai, N., et al. 2009. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect. 59:207-212.
12. Kohno, S., H. Kida, M. Mizuguchi, and J. Shimada, for the S-021812 Clinical Study Group. 2010. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob. Agents Chemother. 54:4568-4574.
13. Kohno, S., et al. 2011. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob. Agents Chemother. 55:2803-2812.
14. Medeiros, R., et al. 2007. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir. Ther. 12:571-576. (Pubitemid 47041157)
15. Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
16. Nicholson, K. G., et al. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355:1845-1850. (Pubitemid 30311875)
17. Osborne, R. H., G. Hawthorne, M. Panicolaou, and Y. Wegmueller. 2000. Measurement of rapid changes in health outcomes in people with influenza symptoms. J. Outcomes Res. 4:15-30.
18. Pizzorno, A., X. Bouhy, Y. Abed, and G. Boivin. 2011. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J. Infect. Dis. 203:25-31.
19. Potier, M., L. Mameli, M. Belislem, L. Dallaire, and S. B. Melanxon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl- α-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296. (Pubitemid 9173017)
20. Sugaya, N., and Y. Ohashi. 2010. Long-acting neuraminidase inhibitor laninamivir octate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother. 54:2575-2582.
21. Taylor, W. R., et al. 2008. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3:e3410.
22. Treanor, J. J., et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283:1016-1024. (Pubitemid 30112215)
23. Watanabe, A., S.-C. Chang, M. J. Kim, D. W. Chu, and Y. Ohashi, for the MARVEL Study Group. 2010. Long-acting neuraminidase inhibitor laninamivir octate versus oseltamivir for treatment of influenza: a doubleblind, randomized, noninferiority clinical trial. Clin. Infect. Dis. 51:1167- 1175.
24. World Health Organization. February 2010, revision date. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/swineflu/h1n1 -guidelines- pharmaceutical-mngt.pdf.
25. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.
26. Zarychanski, R., et al. 2010. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 182:257-264.